Reni J. Benjamin
Stock Analyst at Citizens
(3.33)
# 999
Out of 5,241 analysts
27
Total ratings
40%
Success rate
8.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Reiterates: Market Outperform | $10 | $1.86 | +437.63% | 1 | Apr 28, 2026 | |
| STRO Sutro Biopharma | Maintains: Market Outperform | $35 → $41 | $38.97 | +5.21% | 2 | Apr 23, 2026 | |
| WHWK Whitehawk Therapeutics | Initiates: Market Outperform | $8 | $4.70 | +70.21% | 1 | Apr 16, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Market Outperform | $5 → $8 | $2.00 | +300.00% | 1 | Apr 14, 2026 | |
| BCAX Bicara Therapeutics | Reiterates: Market Outperform | $31 | $20.23 | +53.24% | 2 | Mar 31, 2026 | |
| IMMX Immix Biopharma | Reiterates: Market Outperform | $23 | $9.94 | +131.39% | 1 | Mar 27, 2026 | |
| LYEL Lyell Immunopharma | Initiates: Market Outperform | $34 | $17.92 | +89.73% | 1 | Mar 9, 2026 | |
| IOVA Iovance Biotherapeutics | Upgrades: Market Outperform | $5 | $3.45 | +44.93% | 2 | Mar 3, 2026 | |
| IMMP Immutep | Initiates: Market Outperform | $10 | $0.52 | +1,824.19% | 2 | Feb 23, 2026 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $16.87 | +137.11% | 4 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $32 | $23.93 | +33.72% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $348 → $396 | $293.27 | +35.03% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $5 → $8 | $3.07 | +160.59% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 | $9.22 | +160.30% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $108.64 | - | 1 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $0.52 | +482.41% | 1 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $4.48 | -33.04% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.27 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $10 | $4.45 | +124.72% | 1 | Aug 12, 2025 |
Compass Therapeutics
Apr 28, 2026
Reiterates: Market Outperform
Price Target: $10
Current: $1.86
Upside: +437.63%
Sutro Biopharma
Apr 23, 2026
Maintains: Market Outperform
Price Target: $35 → $41
Current: $38.97
Upside: +5.21%
Whitehawk Therapeutics
Apr 16, 2026
Initiates: Market Outperform
Price Target: $8
Current: $4.70
Upside: +70.21%
Allogene Therapeutics
Apr 14, 2026
Maintains: Market Outperform
Price Target: $5 → $8
Current: $2.00
Upside: +300.00%
Bicara Therapeutics
Mar 31, 2026
Reiterates: Market Outperform
Price Target: $31
Current: $20.23
Upside: +53.24%
Immix Biopharma
Mar 27, 2026
Reiterates: Market Outperform
Price Target: $23
Current: $9.94
Upside: +131.39%
Lyell Immunopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $34
Current: $17.92
Upside: +89.73%
Iovance Biotherapeutics
Mar 3, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $3.45
Upside: +44.93%
Immutep
Feb 23, 2026
Initiates: Market Outperform
Price Target: $10
Current: $0.52
Upside: +1,824.19%
Summit Therapeutics
Jan 30, 2026
Reiterates: Market Outperform
Price Target: $40
Current: $16.87
Upside: +137.11%
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $23.93
Upside: +33.72%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $293.27
Upside: +35.03%
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $3.07
Upside: +160.59%
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $9.22
Upside: +160.30%
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $108.64
Upside: -
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.52
Upside: +482.41%
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $4.48
Upside: -33.04%
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.27
Upside: -
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $4.45
Upside: +124.72%